A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Oxycodone Hydrocodone Bitartrate and Homatropine Methylbromide

Oxycodone vs Hydrocodone Bitartrate and Homatropine Methylbromide — $737.4M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Opioid Agonist
Oxycodone
Brand: OXAYDO
First FDA approval:
Opioid Agonist
Hydrocodone Bitartrate and Homatropine Methylbromide
Brand: Hycodan
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.045Per unit
$0.098Per unit
Average NADACAcross all dosage forms and strengths
$2.87Up to $32.73
$0.675Up to $0.964
Generic manufacturersActive ANDA holders — FDA Orange Book
1867 total ANDAs filed
66 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$737.4MFull year
Full year
Part D claims (CY24)Total fills, all strengths
14.7M4.7M beneficiaries
— beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$50Per claim, all NDCs
Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
254Substantial friction
Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
DiscontinuedSee drug profile
DiscontinuedSee drug profile
Generic availableFDA Orange Book
Yes18 manufacturers
Yes6 manufacturers